ERBB2 and breast cancer: Conversely, our previous study of a total of 843 early HER2-positive BC patients (588 of whom received adjuvant trastuzumab for 1 year) demonstrated a significant association between a low baseline NLR and improved DFS among patients receiving trastuzumab but not in HER2-positive BC patients not receiving trastuzumab [16].